{"id":4586,"date":"2021-12-02T13:05:12","date_gmt":"2021-12-02T12:05:12","guid":{"rendered":"https:\/\/pharmavalue.it\/?p=4586"},"modified":"2021-12-23T11:38:37","modified_gmt":"2021-12-23T10:38:37","slug":"new-criteria-for-accessing-fund-5-of-law-326-2003","status":"publish","type":"post","link":"https:\/\/pharmavalue.it\/en\/new-criteria-for-accessing-fund-5-of-law-326-2003\/","title":{"rendered":"New criteria for access to the 5% fund of Law 326\/2003"},"content":{"rendered":"<p>On 30 November 2021, AIFA defined the new access criteria for Law 326\/2003.<\/p>\n<p>This law was supplemented by Law No. 175 of 10 November 2021 on the treatment of rare diseases.<\/p>\n<p>We have produced a summary in graphical format of the inclusion and exclusion criteria for access to the 326 fund, highlighting some of the elements that can be an obstacle to a clinician's successful application.<\/p>\n<p>For Aifa, a repeat use is the request of a drug, for the same indication, to different patients.<\/p>\n<p>Operational procedures include:<br \/>\n1. The centre of documented experience verifies the inclusion and exclusion criteria.<br \/>\n2. If the inclusion and exclusion criteria match, the centre can send its request for access to the fund to AIFA.<\/p>\n<p>&nbsp;<\/p>\n<div class=\"_df_book df-lite\" id=\"df_4589\"  _slug=\"nuovi-criteri-di-accesso-al-fondo-5-della-legge-326-2003\" data-title=\"nuovi-criteri-di-accesso-al-fondo-5-della-legge-326-2003\" wpoptions=\"true\" thumbtype=\"\" ><\/div><script class=\"df-shortcode-script\" nowprocket type=\"application\/javascript\">window.option_df_4589 = {\"outline\":[],\"backgroundColor\":\"eeeeee\",\"duration\":\"0\",\"autoEnableOutline\":\"false\",\"autoEnableThumbnail\":\"false\",\"overwritePDFOutline\":\"false\",\"enableDownload\":\"true\",\"direction\":\"1\",\"pageSize\":\"0\",\"pageMode\":\"1\",\"soundEnable\":\"false\",\"autoPlay\":\"false\",\"source\":\"https:\\\/\\\/pharmavalue.it\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/NUOVI-CRITERI-DI-ACCESSO-ALLA-LEGGE-326_2003_S4.pdf\",\"wpOptions\":\"true\"}; if(window.DFLIP && window.DFLIP.parseBooks){window.DFLIP.parseBooks();}<\/script>","protected":false},"excerpt":{"rendered":"<p>Il 30 novembre 2021 AIFA ha definito i nuovi criteri di accesso alla Legge 326\/2003. Tale legge e\u0300 stata integrata dalla Legge 10 novembre 2021 n.175 sulla cura delle malattie rare. Abbiamo realizzato una sintesi in formato grafico dei criteri di inclusione e di esclusione dell\u2019accesso al fondo 326, attenzionando alcuni elementi che possono essere [&hellip;]<\/p>\n","protected":false},"author":314,"featured_media":4588,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","footnotes":""},"categories":[9,64],"tags":[46,14,60,33],"class_list":["post-4586","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-appunti","category-malattie-rare","tag-aifa","tag-appuntidipharmavalue","tag-farmaci-orfani","tag-legge-326"],"_links":{"self":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts\/4586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/users\/314"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/comments?post=4586"}],"version-history":[{"count":0,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts\/4586\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/media\/4588"}],"wp:attachment":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/media?parent=4586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/categories?post=4586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/tags?post=4586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}